About
Cannabotech develops advanced medical solutions for cancer, inflammation, and chronic pain. Its drug formulation method utilizes pure clinical, botanical qualities with the aim of creating an effective cure for these long-term illnesses.
The company uses traditional botanical resources that have proven both therapeutic and safe in order to accelerate medicinal development and swiftly reach mainstream consumers who are looking for innovative and certified medical solutions. Cannabotech harnessed the benefits of cannabinoids and medicinal mushrooms and has created its proprietary and patent-pending formula: M²CBD.
Cannabotech focuses on three classes of medical solutions: integrative care, preventive medicine, and botanical drugs.
Funding history · 3 rounds · $29.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did CannaboTech become a publicly traded company?
- CannaboTech became public on the TASE in July 2021, with a valuation of $110 million.
- What significant financial event occurred for CannaboTech in August 2024?
- In August 2024, CannaboTech, after raising 30 million NIS from the public, was reportedly on its way to a creditors' arrangement.
- What was a key development for CannaboTech in the UK in March 2024?
- In March 2024, CannaboTech announced a major deal in the UK, indicating market expansion into the region.
- What expansion plans did CannaboTech announce for Thailand in January 2024?
- In January 2024, CannaboTech signed an agreement to establish three concept stores for its preventive medicine brand in Thailand.
- What was the outcome of CannaboTech's pre-clinical trials for a cancer drug in January 2023?
- In January 2023, CannaboTech successfully completed two pre-clinical trials for the safety of its cancer drug.
- What breakthrough did CannaboTech announce regarding its pancreatic cancer drug in July 2022?
- In July 2022, CannaboTech announced a breakthrough in its pancreatic cancer drug, showing a combined anti-cancer effect between cannabis and mushroom for the first time.
- What partnership did CannaboTech establish in April 2022?
- In April 2022, CannaboTech partnered with go NXT LVL to manufacture oncology products in California.
- What were the results of CannaboTech's 'Integrative-Colon' product experiments in March 2022?
- In March 2022, CannaboTech's 'Integrative-Colon' products eliminated over 90% of colon cancer cells in a cell model experiment.
- What was the reported efficacy of CannaboTech's 'IntegrativePain' products in February 2022?
- In February 2022, CannaboTech's 'IntegrativePain' products demonstrated an 80%-100% reduction in inflammatory pain.